Hidesaku Asakura

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview by Shinya Yamada SciProfiles Scilit Preprints.org Google Scholar and Hidesaku Asakura SciProfiles Scilit Preprints.org Google Scholar Hidesaku Asakura is a clinical professor at the Department of Hematology at Kanazawa University He [...] Hidesaku Asakura is a clinical professor at the Department of Hematology at Kanazawa University Hospital.

Matthieu Schmidt and colleagues aimed to establish the clinical characteristics and outcomes of patients with COVID-19 and respiratory failure treated with extracorporeal membrane oxygenation (ECMO). Among 83 patients, 30 (36%) died, 35 (42%) had major bleeding events, and four (5%) had a haemorrhagic stroke. When discussing the effectiveness of ECMO, an essential aspect is assessing whether the associated bleeding events are adverse incidents, or events resulting from abnormal coagulation.

Abstract A high rate of thrombotic complications, such as pulmonary embolism, has been linked to mortality in COVID-19, and appropriate treatment of thrombosis is important for lifesaving. Although heparin is frequently used to treat thrombotic pathology in COVID-19, pulmonary embolism is still seen in severe cases.